Prospective derivation of a living organoid biobank of colorectal cancer patients.

Prospective derivation of a living organoid biobank of colorectal cancer patients.
复制标题

DOI:
10.1016/j.cell.2015.03.053
复制
发表时间:
2015-05-07
期刊:
影响因子:
64.5
通讯作者:
Clevers H
Clevers H
中科院分区:
生物学1区
文献类型:
--
作者:
van de Wetering M;Francies HE;Francis JM;Bounova G;Iorio F;Pronk A;van Houdt W;van Gorp J;Taylor-Weiner A;Kester L;McLaren-Douglas A;Blokker J;Jaksani S;Bartfeld S;Volckman R;van Sluis P;Li VS;Seepo S;Sekhar Pedamallu C;Cibulskis K;Carter SL;McKenna A;Lawrence MS;Lichtenstein L;Stewart C;Koster J;Versteeg R;van Oudenaarden A;Saez-Rodriguez J;Vries RG;Getz G;Wessels L;Stratton MR;McDermott U;Meyerson M;Garnett MJ;Clevers H

文献摘要

参考文献

被引文献

相似文献

在基于Rspondin的三维培养物中,来自多个器官的Lgr 5干细胞形成不断扩大的上皮类器官,这些上皮类器官保持其组织身份。在这里,我们报告了20例连续结直肠癌(CRC)患者的肿瘤类器官培养的建立。对于大多数人来说,类器官也是从相邻的正常组织中产生的。类器官与原始肿瘤非常相似。“活体生物库”中的遗传变化谱与之前对CRC的大规模突变分析一致。基因表达分析表明,主要的CRC分子亚型的代表。肿瘤类器官适合高通量药物筛选,允许检测基因-药物关联。例如,单一类器官培养物对Wnt分泌(豪猪)抑制剂非常敏感,并且在负Wnt反馈调节因子RNF 43中携带突变,而不是在APC中。类器官技术可以填补癌症遗传学和患者试验之间的差距,补充基于细胞系和异种移植的药物研究,并允许个性化治疗设计。
In Rspondin-based three-dimensional cultures, Lgr5 stem cells from multiple organs form ever-expanding epithelial organoids that retain their tissue identity. Here we report the establishment of tumor organoid cultures from 20 consecutive colorectal carcinoma (CRC) patients. For most, organoids were also generated from adjacent normal tissue. Organoids closely resemble the original tumor. The spectrum of genetic changes within the 'living biobank' agrees well with previous large-scale mutational analyses of CRC. Gene expression analysis indicates that the major CRC molecular subtypes are represented. Tumor organoids are amenable to high-throughput drug screens allowing detection of gene-drug associations. As an example, a single organoid culture was exquisitely sensitive to Wnt secretion (porcupine) inhibitors and carried a mutation in the negative Wnt feedback regulator RNF43, rather than in APC. Organoid technology may fill the gap between cancer genetics and patient trials, complement cell line- and xenograft-based drug studies and allow personalized therapy design.
DOI: 10.1038/ng.936
发表时间: 2011-09-04
期刊: Nature genetics
影响因子: 30.8
作者:
通讯作者: --
DOI: 10.1101/gad.235473.113
发表时间: 2014-02-15
影响因子: 10.5
作者:
de Lau W;Peng WC;Gros P;Clevers H
通讯作者: Clevers H
DOI: 10.1038/nrc1299
发表时间: 2004-03
期刊: Nature reviews. Cancer
影响因子: --
作者:
通讯作者: --
DOI: 10.1038/nature11019
发表时间: 2012-05-10
期刊: NATURE
影响因子: 64.8
作者:
Hao, Huai-Xiang;Xie, Yang;Cong, Feng
通讯作者: Cong, Feng
DOI: 10.1038/sj.onc.1210098
发表时间: 2007-05-03
期刊: ONCOGENE
影响因子: 8
作者:
Ivanov, I.;Lo, K. C.;Ionov, Y.
通讯作者: Ionov, Y.